Organic acids and the uremie syndrome: Protein metabolite hypothesis in the progression of chronic renal failure

Seminars in Nephrology

Volumn 16, Issue 3, 1996, Pages 167-182

  Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AST 120; CARBOXYLIC ACID; CREATININE; HIPPURIC ACID; INDICAN; PARA CRESOL; PHENOL DERIVATIVE; PROPIONIC ACID DERIVATIVE; SERUM ALBUMIN; SORBENT; UREMIC TOXIN;

ALBUMIN BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN METABOLISM; PROTEIN RESTRICTION; REVIEW; UREMIA;

ANIMALS; FURANS; HIPPURATES; HUMANS; INDOLES; KIDNEY FAILURE, CHRONIC; PROPIONIC ACIDS; PROTEIN BINDING; PROTEINS; RATS;

EID: 0030002319     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (204)

1. Bergström J, Furst P: Uremie toxins. Kidney Int 13:S9S12, 1978 (supplS)
2. Massry SG: Is parathyroid hormone a uremie toxin? Nephron 19:125-30, 1977
3. Massry SG, Goldstein DA: The search for uremie toxin(s) "X" "X" = PTH. Clin Nephrol 11:181-189, 1979
4. Massry SG: Parathyroid hormone: A uremic toxin. Adv Exp Med Biol 223:1-17, 1987
5. Wills MR: Uremic toxins, and their effect on intermediary metabolism. Clin Chem 31:5-13, 1985
6. Motojima M, Nishijima F, Ikoma M, el al: Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 40:461-469, 1991
7. Kurnick NB, Lindsey PA: Compensatory renal hypertrophy in parabiotic mice. Lab Invest 10:45-48, 1968
8. Obertop H, Malt RA: Lost mass and excretion as stimuli to parabiotic compensatory renal hypertrophy. Am J Physiol 232:F405-408, 1977
9. Harris RH, Best CF: Circulatory retention of urinary factors as a stimulus to renal growth. Kidney Int 12:305-312, 1977
10. Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs hypertrophy in experimental glomerular sclerosis. Kidney Int 35:654-660, 1989
11. Yoshida Y, Kawamura T, Ikoma M, el al: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36:626-635, 1989
12. Doi T, Striker LJ, Quaife C, et al: Progressive glomerular sclerosis develops in transgenic mice chronically expressing growth hormone and growth-hormone-releasing factor but not in those expressing insulin-like growth factor-1. Am J Pathol 131:398-403, 1988
13. MacKay K, Striker LJ, Stauffer JW, et al: Relationship of glomerular hypertrophy and sclerosis: Studies in SV40 transgenic mice. Kidney Int 37:741-748, 1990
14. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
15. Fogo A, Ichikawa I: Evidence for the central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 9:329-342, 1989
16. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96-104, 1994
17. Niwa T, Ise M, Miyazaki T: Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 14:207 212, 1994
18. Schools AC, Mikkers F, Cramers C, et al: Uremie toxins and the elusive middle molecules. Nephron 38:1-8, 1984
19. Niwa T: Metabolic profiling with gas chromatographymass spectrometry and its application to clinical medicine. J Chromatogr 379:313-345, 1986
20. Vanholder RC, Ringoir SMG: The uraemic syndrome, in Cameron AM, Davison J-P, Grünfeld D, et al (eds): Oxford Textbook of Clinical Nephrology. Oxford, Oxford University Press, 1992, pp 1236-1250
21. Vanholder R, De Smet R, Hsu C, et al: Uremie toxicity: The middle molecule hypothesis revisited. Semin Nephrol 14:205-218, 1994
22. Niwa T, Takeda N, Miyazaki T, et al: Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremie serum. Nephron 69:438-443, 1995
23. Niwa T, Miyazaki S, Katsuzaki T, et al: Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 48:771-778, 1995
24. 2-m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremie serum. Kidney Int (in press) 1996
25. Schools AC, Gerlag PGG, Mulder AW, et al: Liquidchromalographic profiling of solutes in serum of uremie patienls undergoing hemodialysis and chronic ambulatory peritoneal dialysis (CAPD); high concentralions of pseudouridine in CAPD palienls. Clin Chem 34:91-97, 1988
26. Nakamura K, lenaga K, Nakano K, et al: Creatol, a creatinine metabolite, as a useful determinant of renal function. Nephron 66:140-6, 1994
27. Niwa T, Asada H, Tsutsui S, et al: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 15:181-185, 1995
28. Niwa T, Yazawa T, Kodama T, et al: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56:241-245, 1990
29. Niwa T, Yazawa T, Maeda K: Melhods for removal of prolein-bound metaboliles accumulaled in uremie serum. Artif Organs 14:228-229, 1991 (suppl4)
30. Niwa T, Emoto Y, Maeda K, et al: Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patienls. Nephrol Dial Transplanl 6:105-109, 1991
31. Slange J, Ramlow W, Mitzner S, el al: Dialysis againsl a recycled albumin solution enables the removal of albuminbound toxins. Artif Organs 17:809-813, 1993
32. Zimmerman L, Fürst P, Bergström J, et al: A new glycine containing compound with a blocked amino group from uremie body fluids. Clin Nephrol 14:107-111, 1980
33. Zimmerman L, Jornvall H, Bergström J, et al: Characterization of middle molecule compounds. Artif Organs 4:3336, 1981 (suppl)
34. Zimmerman L, Jornvall H, Bergström J, et al: Characterization of a double conjugate in uremie body fluids. FEBS Lett 129:237-240, 1981
35. Zimmerman L, Bergström J, Jomvall H, et al: A method for separation of middle molecules by high performance liquid chromatography: Application in studies of glucuronyl-o-hydroxyhippurate in normal and uremie subjects. Clin Nephrol 25:94-100, 1986
36. Faguer P, Man NK, Cueille G, et al: Drug interaction in middle molecule analysis, with special reference to acetylsalicylic acid. Artif Organs 8:226-229, 1984
37. Asaba H, Zimmerman L, Bergström J, et al: On drug artifacts in middle molecule analysis. Nephron 39:73-76, 1985
38. Monti JP, Gallice P, Crevat A, et al: Identification by nuclear magnetic resonance and mass spectrometry of a glucuronic conjugate of o-hydroxybenzoic acid in normal urine and uremie plasma. Clin Chem 31:1640-1643, 1985
39. Makita Z, Bucala R, Rayfield EJ, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
40. Gejyo F, Brancaccio D: Beta-2-microglobuIin: A possible new uremie toxin?. Int J Artif Organs 11:3-5, 1988
41. Hicks JM, Young DS, Wooton IDP: Abnormal blood constituents in acute renal failure. Clin Chim Acta 7:623 633, 1962
42. Hicks JM, Young DS, Wooton IDP: The effect of uraemic blood constituents on certain cerebral enzymes. Clin Chim Acta 9:228-235, 1964
43. Record NB, Prichard JW, Gallagher BB, et al: Phenolic acids in experimental uremia. Arch Neurol 21:387-394, 1969
44. Ross P, Wooton IDP: Glycine conjugation and toxicity of phenolic acids. Clin Chim Acta 9:434-440, 1964
45. Schools AC, Homan HR, Gladdines MM, et al: Screening of UV-absorbing solutes in uremie serum by reversed phase HPLC-Changes of blood levels in different therapies. Clin Chim Acta 146:37-51, 1985
46. Kaplan B, Gotfried M, Cojocaru M, et al: Bound amino acids in uremie sera: Search for peptidic middle molecules by preparative polyacrylamide gel electrophoresis and high performance liquid chromatography. Clin Chim Acta 185:119-130, 1989
47. Bultitude FW, Newham SJ: Identification of some abnormal metabolites in plasma from uremie subjects. Clin Chem 21:1329-1334, 1975
48. Schools AC, Mikkers FEP, Cramers, et al: Profiling of uremie serum by high-resolution gas chromatography-electron-impact, chemical ionization mass spectrometry. J Chromatogr 164:1-8, 1979
49. Schools AC, Leclercq PA: Chemical ionization mass . speclrometry of trimethylsilylated carbohydrates and organic acids retained in uremie serum. Biomed Mass Spectrom 6:502-507, 1979
50. Pinkslon D, Spileller G, von Henning H, el al: Highresolulion gas chromatography-Mass spectrometry of the methyl esters of organic acids from uremie hemofillrates. J Chromalogr 223:1-19, 1981
51. Schools AC, Mikkers F, Claessens HA, et al: Characlerizalion of uremie "middle molecular" fraclions by gas chromatography, mass speclrometry, isotachophoresis and liquid chromatography. Clin Chem 28:45-49, 1982
52. Masimore XL, Veening H, Vandenheuvel WJA, el al: Gas chromatography-mass spectrometry of metabolites in hemodialysis fluid. J Chromatogr 143:247-257, 1977
53. Schools AC, Dijkslra JB, Ringoir SM, el al: Are the classical markers sufficient to describe uremie solule accumulation in dialyzed patienls? Hippurates reconsidered. Clin Chem 34:1022-1029, 1988
54. Niwa T, Ohki T, Maeda K, et al: A gas chromato-graphic-mass spectrometric assay for nine hydroxyphenolic acids in uremie serum. Clin Chim Acta 96:247-254, 1979
55. Niwa T, Ohki T, Maeda K, et al: Pattern of aliphatic dicarboxylic acids in uremie serum including a new organic acid, 2,4-dimethyladipic acid. Clin Chim Acta 99:71-83, 1979
56. Rabiner SF, Molinas F: The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 49:346-351, 1970
57. Molinas FC: Inhibition by phenol and phenolic acids of platelet release reaction. Thromb Diath Haemorrh 30:334-338, 1973
58. Wardle EN: A study of the effects of possible toxic metabolites of uraemia on red cell metabolism. Acta Hematol 43:129-143, 1970
59. Niwa T, Yoshizumi H, Emoto Y, et al: Accumulation of quinolinic acid in uremie serum and its removal by hemodialysis. Clin Chem 37:159-161, 1991
60. Lapin IP: Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neurol Trans 42:37-43, 1978
61. Veneziale CM, Walter P, Kneer N, et al: Influence of L-tryptophan and its metabolites on gluconeogenesis in the isolated perfused liver. Biochemistry 6:2129-2138, 1967
62. Kawashima Y, Sanaka T, Sugino N, et al: Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia. Adv Exp Med Biol 223:69-72, 1987
63. Wolthers BG, Meijer S, Tepper T, et al: The determination of oxalate in haemodialysate and plasma: A means to detect and study 'hyperoxaluria' in haemodialyzed patients. Clin Sci 71:41-47, 1986
64. Salyer WR, Keren D: Oxalosis as a complication of chronic renal failure. Kidney Int 4:61-66, 1973
65. Milgram JW, Salyer WR: Secondary oxalosis of bone in chronic renal failure. J Bone Joint Surg 56A:387-395, 1974
66. Fayemi AO, Ali M, Braun EV: Oxalosis in hemodialysis patients. Arch Pathol Lab Med 103:58-62, 1979
67. Celasun B, Safali M, Yenicesu M: Secondary oxalosis of bone in a dialysis patient. Scand J Urol Nephrol 29:211-214, 1995
68. Abuleo JO, Schwanz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 152:1517-1520, 1992
69. Levin RI, Kantoff PW, Jaffe EA: Uremic levels of oxalic acid suppress replication and migration of human endothelial cells. Arteriosclerosis 10:198-207, 1990
70. De Torrente A, Glazer GB, Gulyassy P: Reduced in vitro binding of tryptophan by plasma in uremia. Kidney Int 6:222-229, 1974
71. Saito A, Niwa T, Maeda K, et al: Tryptophan and indolic tryptophan metabolites in chronic renal failure. Am J Clin Nutr 33:1402-1406, 1980
72. Oie S, Lowenthal DT, Levy G: Protein binding of bilirubin in plasma of anephric patients. J Dial 4:91-100, 1980
73. Lagana A, Liberti A, Morgia C, et al: Determination of indican and tryptophan in normal and uremia patients by high-performance liquid chromatography with a new electrochemical detector. J Chromatogr 378:85-93, 1986
74. Walser M, Hill SB: Free and protein-bound tryptophan in serum of untreated patients with chronic renal failure. Kidney Int 44:1366-1371, 1993
75. Sjöholm I, Kober A, Odar-Cederlöf I, et al: Protein binding of drugs in uremie and normal serum: The role of endogenous binding inhibitors. Biochem Pharmac 25:1205-1213, 1976
76. Ikeda K, Yoshitomi H, Nakayama T, et al: Plasma protein binding of fursemide in renal failure rabbits: Investigation of endogenous protein binding inhibitors. J Pharm Pharmacol 36:663-667, 1984
77. Affrime MB, Blecker DL, Lyons PJ, et al: The effect of renal transplantation on plasma protein binding. J Dial 3:207-218, 1979
78. Robertz GM, Dengler HJ: Endogenous ligand(s) decrease drug-protein binding in uremie sera: A fluorescence probe study. Klin Wochenschr 61:649-653, 1983
79. Mabuchi H, Nakahashi H: Displacement by anionic drugs of endogenous ligands bound to albumin in uremie serum. Ther Drug Monit 10:261-264, 1988
80. Vanholder R, Van Landschoot N, De Smet R, et al: Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney Int 33:996-1004, 1988
81. Vanholder R, De Smet R, Ringoir S: Factors influencing drug protein binding in patients with end stage renal failure. Eur J Clin Pharmacol 44:517-21, 1993 (Suppl 1)
82. Craig WA, Evenson MA, Sarver KP, et al: Correction of protein binding defect in uremie sera by charcoal treatment. J Lab Clin Med 87:637-647, 1976
83. Kober A, Sjöholm I, Borga O, et al: Protein binding of diazepam and digitoxin in uremie and normal serum. Biochem Pharm 28:1037-1042, 1979
84. Grafnetterova J, Grafnetter D, Schuck O, et al: The effect of endogenous compounds, isolated from sera of uremic proteins, on chloramphenicol binding to proteins. Biochem Pharm 28:2923-2928, 1979
85. Lichtenwalner DM, Sun B, Lorber B, et al: Correction of drug binding defects in uremia m vitro by anion exchange resin treatment. Biochem Pharmacol 31:3483-3487, 1982
86. Depner TA, Stanfel LA, Jarrard EA, et al: Impaired plasma phenytoin binding in uremia. Nephron 25:231-237, 1980
87. Depner TA, Gulyassy PF: Plasma protein binding in uremia: Extraction and characterization of an inhibitor. Kidney Int 18:86-94, 1980
88. Lichtenwalner DM, Suh B, Lorber B, et al: Partial purification and characterization of the drug-binding-defect inducer in uremia. J Lab Clin Med 97:72-81, 1981
89. Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 20:511-8, 1981
90. Depner TA, Sanaka T, Stanfel LA: Suppression of para-aminohippurate transport in the isolated perfused kidney by an inhibitor of protein binding in uremia. Am J Kidney Dis 3:280-286, 1984
91. McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98:730-740, 1981
92. Gulyassy FF, Bottini AT, Jarrard EA, et al: Isolation of inhibitors of ligand: Albumin-binding from uremie body fluids and normal urine. Kidney Int 24:s238-s242, 1983
93. Gulyassy PF, Bottini AT, Stanfel LA, et al: Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int 30:391-398, 1986
94. Gulyassy PF, Jarrard E, Stanfel LA: Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Biochem Pharm 36:4215-4220, 1987
95. Dasgupta A, Malik S: Fast atom bombardment mass spectrometric determination of the molecular weight range of uremie compounds that displace phenytoin from protein binding: absence of midmolecular uremie toxins. Am J Nephrol 14:162-168, 1994
96. Bowmer CJ, Lindup WE: Decreased drug binding in uraemia: Effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharm 31:319-323, 1982
97. Niwa T, Takeda N, Tatematsu A, et al: Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremie serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34:2264-2267, 1988
98. Takeda N, Niwa T, Tatematsu A, et al: Identification and quantification of a protein-bound ligand in uremie serum. Clin Chem 33:682-685, 1987
99. Lichtenwalner DM, Suh B: Isolation and chemical characterization of 2-hydroxybenzoylglycine as a drug binding inhibitor in uremia. J Clin Invest 71:1289-1296, 1983
100. Suh B, Wadsworth SJ, Lichtenwalner DM: Demonstration of 2-hydroxybenzoylglycine as a drug binding inhibitor in newborn infants. J Clin Invest 80:1125-1131, 1987
101. Kramer B, Seligson H, Baltrush H, et al: The isolation of several aromatic acids from the hemodialysis fluids of uremie patients. Clin Chim Acta 11:363-371, 1965
102. Liebich HM, Bubeck JI, Pickert A, et al: Hippuric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in serum and urine. Analytical approaches and clinical relevance in kidney diseases. J Chromatogr 500:615-627, 1990
103. Liebich HM, Pickert A, Tetschner B: Gas Chromatographie and gas chromatographic-mass spectrometric analysis of organic acids in plasma of patients with chronic renal failure. J Chromatogr 289:259-266, 1984
104. Liebich HM, Risler T, Fischer U, et al: Gas Chromatographie determination of hippuric acid and a furancarboxylic acid in plasma of patients with kidney disease. J Chromatogr 399:291-294, 1987
105. Pickert A, Bauerle A, Liebich HM: Determination of hippuric acid and furanic acid in serum of dialysis patients and control persons by high-performance liquid chromatography. J Chromatogr 495:95-104, 1989
106. Zimmerman L, Jornvall H, Bergström J: Phenylacetylglutamine and hippuric acid in uremie and healthy subjects. Nephron 55:265-271, 1990
107. Spustova V, Gajdos M, Opatrny K Jr, et al: Serum hippurate and its excretion in conservatively treated and dialysed patients with chronic renal failure. Physiol Res 40:599-606, 1991
108. Spustova V, Dzurik R, Gerykova M: Hippurate participation in the inhibition of glucose utilization in renal failure. Czech Med 10:79-89, 1987
109. Spustova V, Cernay P, Golier I: Inhibition of glucose utilization in uremia by hippurate: liquid Chromatographie isolation and mass spectrometric and nuclear magnetic resonance spectroscopic identification. J Chromatogr 490:186-192, 1989
110. Schools AC, De Vries PM, Thiemann R, et al: Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin Chim Acta 185:91107, 1989
111. Schools AC, Peelers JA, Gerlag PG: Effecl of hemodialysis on serum concenlralions of HPLC-analyzed accumulating solutes in uremia. Nephron 53:208-217, 1989
112. Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremie markers for quantification of dialysis efficacy. Clin Chem 38:1429-1436, 1992
113. Igarashi P, Gulyassy P, Stanfel L, el al: Plasma hippurate in renal failure: High-performance liquid chromatography melhod and clinical application. Nephron 47:290-294, 1987
114. Vanholder R, De Smet R, Schools A, el al: Correlation of a colorimelric and a HPLC method for the determination of serum hippuric acid concentrations in uremia. Nephron 49:164-168, 1988
115. Schools AC, Verheggen TP, De Vries PM, el al: Ultraviolet-absorbing organic anions in uremie serum separated by capillary zone electrophoresis, and quantification of hippuric acid. Clin Chem 36:435-440, 1990
116. Vanholder R, De Smet R, Gervasio R, el al: In vivo solute elimination of paired fillralion dialysis. Int J Artif Organs 14:23-27, 1991
117. Kramer BK, Picken A, Hohmann C, el al: In vivo clearance and elimination of nine marker substances during hemofiltration with different membranes. Int J Artif Organs 15:408-412, 1992
118. Suh B, Lee HW, Hong SY, el al: A new HPLC analytical method for o-hydroxyhippuric acid in uremie serum. J Biochem Biophys Melhods 13:211-220, 1986
119. Gallice P, Monli JP, Crevai A, el al: A compound from uremie plasma and from normal urine isolated by liquid chromatography and identified by nuclear magnetic resonance. Clin Chem 31:30-34, 1985
120. Spileller M, Spiteller G: Trennung und Charakterisierung saurer Harnbestandleile. J Chromatogr 164:253-317, 1979
121. Mabuchi H, Nakahashi H: Profiling of endogenous ligand solutes that bind to serum proleins in sera of palienls with uremia. Nephron 43:110-116, 1986
122. Mabuchi H, Nakahashi H: Isolation and characterization of an endogenous drug-binding inhibitor presenl in uremic serum. Nephron 44:277-281, 1986
123. Takeda N, Niwa T, Maeda K, el al: Rapid assay for indoxyl sulphale in uremie serum by internal-surface reversed-phase high-performance liquid chromatography. J Chromatogr 431:418-423, 1988
124. Niwa T, Takeda N, Maeda K, el al: Accumulation of furancarboxylic acids in uremie serum as inhibitors of drug-binding. Clin Chim Acta 173:127-138, 1988
125. Lindup WE, Henderson SJ, Barker CE: Drug binding in renal disease, in Belpaire F, Bogaert M, Tillement JP, el al (eds): Plasma Bindings of Drugs and its Consequences. Ghenl, Academia Press, 1991, pp 103-120
126. Collier R, Lindup WE: Drug binding defecl of uraemic plasma: Inhibitory effect of furanoid acids. Br J Clin Pharmacol 23:650-651, 1987
127. Mabuchi H, Nakahashi H: Underestimation of serum albumin by the bromcresol purple melhod and a major endogenous ligand in uremia. Clin Chim Acta 167:89-96, 1987
128. Glass RL, Krick TP, Sand DM, el al: Furanoid falty acids from fish lipids. Lipids 10:695-702, 1975
129. Hannemann K, Puchta V, Simon E, el al: The common occurrence of furan fatty acids in plants. Lipids 24:296-298, 1989
130. McTigue JJ, Henderson SJ, Lindup WE: Excretion of the uraemic metabolite 3-carboxy-4-methyl-5-propyl-2-furan-propanoic acid in human urine. Nephron 55:214-215, 1990
131. Sato M, Koyama M, Miyazaki T, el al: Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremie patients. Nephron (in press) 1996
132. Henderson SJ, Lindup WE: Interaction of 3-carboxy4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin. Biochem Pharm 40:2543-2548, 1990
133. Henderson SJ, Lindup WE: Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263:54-60, 1992
134. Niwa T, Kawagishi I, Ohya N: Rapid assay for furancarboxylic acid accumulated in uremie serum using highperformance liquid chromatography and on-line mass spectrometry. Clin Chim Acta 226:89-94, 1994
135. Niwa T, Aiuchi T, Nakaya K, el al: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremie serum in its albumin-bound and non-dialyzable form. Clin Nephrol 39:92-96, 1993
136. Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferase by a major endogenous ligand substances present in uremie serum. Nephron 49:281-283, 1988
137. Lim CF, Bernard BF, de Jong M, el al: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 76:318-324, 1993
138. Lim CF, Stockigt JR, Curtis AJ, el al: A naturally occurring furan fatty acid enhances drug inhibition of thyroxine binding in serum. Metabolism 42:1468-1474, 1993
139. Everts ME, Lim CF, Moerings EP, el al: Effects of a furan fatty acid and indoxyl sulfate on thyroid hormone uptake in cultured anterior pituitary cells. Am J Physiol 268:E974-979, 1995
140. Bueschkens DH, Stiles ME: Escherichia coli variants for gas and indole production at elevated incubation temperatures. Appl Environ Microbiol 48:601-605, 1984
141. Krstulovic AM, Matzura C: Rapid assay for tryptophanase using reversed-phase high-performance liquid chromatography. J Chromatogr 176:217-224, 1979
142. 14C] indole in the rat. Biochem J 98:266-277, 1966
143. Ludwig GD, Senesky D, Bluemle LW, el al: Indoles in uremia: Identification by countercunent distribution and paper chromatography. Am J Clin Nutr 21:436-450, 1968
144. Stanfel LA, Gulyassy PF, Jarrard EA: Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography. Clin Chem 32:938-942, 1986
145. Barnett AL, Veening H: Liquid Chromatographie study of fluorescent compounds in hemodialysate solutions. Ciin Chem 31:127-130, 1985
146. Niwa T, Tsukushi S, Miyazaki T, el al: Low-protein diet and oral sorbent reduce serum and urine levels of indoxyl sulfate in undialyzed uremie patients. Clin Nephrol (in press)
147. Klahr S, Buerkert J, Purkerson ML: Role of dietary factors in the progression of chronic renal disease. Kidney Int 24:579-587, 1983
148. Klahr S: Low-protein diets and angiotensin-converting enzyme inhibition in progressive renal failure. Am J Kidney Dis 22:114-119, 1993
149. Klahr S, Levey AS, Beck GJ, el al: The effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
150. Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23:647-655, 1983
151. Brenner BM, Meyer TW, Hosteller TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1992
152. El Nahas AM, Masters-Thomas A, Brady SA, el al: Selective effect of low protein diets in chronic renal diseases. Br Med 1289:1337-1341, 1984
153. Mitch WE, Walser M, Steinman TI, el al: The effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med 311:623-629, 1984
154. Mitch WE: The influence of the diet on the progression of renal insufficiency. Annu Rev Med 35:249-264, 1984
155. Mitch WE: Dietary manipulation and progression of chronic renal failure. Child Nephrol Urol 11:134-139, 1991
156. Mitch WE: Dietary protein restriction in chronic renal failure: nutritional efficacy, compliance, and progression of renal insufficiency. J Am Soc Nephrol 2:823-831, 1991
157. Rosman JB, ter Wee PM, Meijer S, el al: Prospective randomized trial of early dietary protein restriction in chronic renal failure. Lancet 2:1291-1296, 1984
158. Rosman JB, ter Wee PM: Relationship between proteinuria and response to low protein diets early in chronic renal failure. Blood Purif 7:52-57, 1989
159. Blachley JD: The role of dietary protein in the progression and symptomatology of chronic renal failure. Am J Med Sci 288:228-234, 1984
160. Bergström J: Discovery and rediscovery of low protein diet. Clin Nephrol 21:29-35, 1984
161. Zeller KR: Effects of dietary protein and phosphorus restriction on the progression of chronic renal failure. Am J Med Sci 294:328-340, 1987
162. Druml W, Mitch WE: Protein-restricted diets and progression of renal failure. Blood Purif 6:285-298, 1988
163. Hunsicker LG: Studies of therapy of progressive renal failure in humans. Semin Nephrol 9:380-394, 1989
164. Ihle BU, Becker GJ, Whitworth JA, el al: The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 321:1773-1777, 1989
165. Teschner M, Heidland A: Progression of chronic renal failure. Pathogenesis and therapeutic aspects. Fortschr Med 107:515-518, 1989
166. Levey AS, Gassman JJ, Hall PM, el al: Assessing the progression of renal disease in clinical studies: Effects of duration of follow-up and regression to the mean: Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol 1:1087-1094, 1991
167. Fouque D, Laville M, Boissel JP, el al: Controlled low protein diets in chronic renal insufficiency: Meta-analysis. Br Med J 304:216-220, 1992
168. Waiser M, Hill SB, Ward L, el al: A crossover comparison of progression of chronic renal failure: Ketoacids versus amino acids. Kidney Int 43:933-939, 1993
169. Gretz N, Meisinger E, Strauch M: Does a low protein diet really slow down the rate of progression of chronic renal failure? Blood Purif 7:33-38, 1989
170. D'Amico G, Gentile MG, Fellin G, el al: Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. Nephrol Dial Transplant 9:1590-1594, 1994
171. Becker GJ, Whilworth JA, Ihle BU, el al: Prevention of progression in non-diabetic chronic renal failure. Kidney Int 45:167-170, 1994 (suppl)
172. Kopple JD: Role of diet in the progression of chronic renal failure: Experience with human studies and proposed mechanisms by which nutrients may retard progression. J Nutr 121:124, 1991 (suppl)
173. Nath KA, Croatt AJ, Hosteller TH: Oxygen consumption and oxidant slress in surviving nephrons. Am J Physiol 258:F1354-F1362, 1990
174. Jarusiripipat C, Shapiro JI, Chan L, el al: Reduclion of remnant nephron hypermetabolism by protein restriction. Am J Kidney Dis 18:367-374, 1991
175. Niwa T, Yazawa T, Ise M, el al: Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremie rats. Nephron 57:8488, 1991
176. Niwa T, Miyazaki T, Hashimoto N, el al: Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremie rats. Am J Nephrol 12:201-206, 1992
177. Sanaka T, Sugino N, Teraoka S, el al: Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 12:97-103, 1988
178. Kanai F, Takahama T, Yamazaki Z, el al: Effect of oral sorbent on experimental uremie rats. Jpn J Nephrol 28:1249-1259, 1986
179. Sakai T, Kumano K, Takara S, el al: Effect of oralsorbent (AST-120) to chronic renal failure (CRF) in rats. Jpn J Nephrol 31:359-365, 1989
180. Yoshida Y, Sakai T, Ise M: Effects of oral adsorbent in the rat model of chronic renal failure. Nephron 62:305-314, 1992
181. Kumano K, Sakai T, Kuwao S, el al: Dietary protein loading and the oral adsorbent AST-120 in the progression of chronic renal failure in the rat. Int J Artif Organs 15:708-714, 1992
182. Takahashi S, Okada K, Shimamura T: Influence of factors in the digestive tract on the progression of chronic renal failure. Jpn J Nephrol 35:1-11, 1993
183. Koide K, Sano M, Takeda F, el al: A study of oral adsorbent in chronic renal failure. Biomater Artif Cells Immobilization Biotechnol 19:147-166, 1991
184. Agatsuma S, Sekino H, Nagoshi T, el al: Indoxylbeta-D-glucuronide, Ihe primary emilter of low-level chemiluminescence in plasma of hemodialysis patients. Clin Chem 40:1580-1586, 1994
185. Niwa T, Miyazaki T, Tsukushi S: Accumulation of indoxyl-/9-D-glucuronide in uremie serum: Suppression of its produclion by oral sorbenl and efficienl removal by hemodialysis. Nephron (in press) 1996
186. Waiser M: Progression of chronic renal failure in man. Kidney Inl 37:1195-1210, 1990
187. Tavares-Almeida I, Gulyassy PF, Depner TA, el al: Aromatic amino acid metabolites as potential protein binding inhibitors in human uremie plasma. Biochem Pharmacol 34:2431-2438, 1985
188. Muting D: Studies on the pathogenesis of uremia: Comparative determinations of glucuronic acid, indican, free and bound phenols in the serum, cerebrospihal fluid, and urine of renal diseases with and without uremia. Clin Chim Acta 12:551-554, 1965
189. Wangle B, Hellstrom K: A gas Chromatographie technique for the analysis of volatile phenols in serum. Scand J Clin Lab Invest 28:477-483, 1971
190. Wengle B, Hellstrom K: Volatile phenols in serum of uraemic patients. Clin Sci 43:493-498, 1972
191. Wardle EN, Wilkinson K: Free phenols in chronic renal failure. Clin Nephrol 6:361-354, 1976
192. Wardle EN: How toxic are phenols? Kidney Int 13:13-15, 1978 (suppl 8)
193. Niwa T, Maeda K, Ohki T, el al: Profiling of uremie ultrafiltrate using high resolution gas chromatography-mass spectrometry-identification of 6 polyphenols. Clin Chim Acta 108:113-119, 1980
194. Niwa T, Maeda K, Ohki T, el al: A gas chromatographic-mass spectrometric analysis for phenols in uremie serum. Clin Chim Acta 110:51-57, 1981
195. Niwa T: Phenol and p-cresol accumulated in uremie serum measured by HPLC with fluorescence detection. Clin Chem39:108-111, 1993
196. Schuck O, Vidlakova M, Erben J, el al: The plasma concentration and renal elimination of phenols in patients with chronic renal failure. Czech Med 12:117-124, 1989
197. Schuck O, Vidlakova M, Erben J: Renal excretion of phenols in patients with chronic renal insufficiency. Nephron 53:279-280, 1989
198. Curtius HCh, Mettler M, Ettlinger L: Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126:569-580, 1976
199. Bakke OM: Studies on the degradation of tyrosine by rat caecal contents. Scand J Gastroenterol 4:603-608, 1969
200. Bone E, Tamm A, Hill M: The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr 29:1448-1454, 1976
201. Levett PN: Detection of Clostridium difficile in faeces by direct gas chromatography. J Clin Pathol 37:117-119, 1984
202. Levett PN, Phillips KD: Gas Chromatographie identification of Clostridium difficile and detection of cytotoxin from a modified selective medium. J Clin
203. Niwa T, Ise M, Miyazaki T, el al: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremie rats. Nephron 65:82-87, 1993
204. Vanholder R, De Smet R, Waterloos MA, el al: Mechanisms of uremie inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47:510-517, 1995